Home » Archive

News

Original content and news from BioSpace, Xconomy, Marketwire and other sources, specific to the region.

News, Syndication »

San Diegan joins state stem cell agency

Posted by sandiegobiotech August 14th, 2014 .
No Comments

San Diegan David Higgins has joined the governing board of California’s stem cell agency.

More...

News, Syndication, UCSD News »

UC San Diego Named One of Best Colleges for Food in U.S.

Posted by sandiegobiotech August 14th, 2014 .
No Comments

The University of California, San Diego been named among the best colleges for food in the United States, according to the Daily Meal website, which nationally covers food and drink topics. UC San Diego came in 19th place in the website’s list of the “75 Best Colleges for Food in America.”

More...

News, Syndication, UCSD News »

UC San Diego Named One of Best Colleges for Food in U.S.

Posted by sandiegobiotech August 14th, 2014 .
No Comments

The University of California, San Diego been named among the best colleges for food in the United States, according to the Daily Meal website, which nationally covers food and drink topics. UC San Diego came in 19th place in the website’s list of the “75 Best Colleges for Food in America.”

More...

News, Syndication, Xconomy »

West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

Posted by sandiegobiotech August 14th, 2014 .
No Comments

[Corrected 8/14/14, 8:11pm. See below.] When Amgen (NASDAQ: AMGN) bought South San Francisco-based Onyx Pharmaceuticals last year for $10.4 billion, it expected great things from Onyx’s…

[[Click headline to continue reading.]]

More...

News, Syndication »

West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

Posted by sandiegobiotech August 14th, 2014 .
No Comments

[Corrected 8/14/14, 8:11pm. See below.] When Amgen (NASDAQ: AMGN) bought South San Francisco-based Onyx Pharmaceuticals last year for $10.4 billion, it expected great things from Onyx’s…

[[Click headline to continue reading.]]

More...

News, Syndication »

Internship program participant aims high

Posted by sandiegobiotech August 14th, 2014 .
No Comments

Xavier University of Louisiana student Kirk McCall might seem like your average college student: energetic, full of potential, and harboring big dreams for the future. But Kirk is also working on sophisticated one-of-a-kind science experiments during his four-summer internship program at Sanford-Burnham and has accumulated lab experience years ahead of most of his peers. When we

Read More

More...

News, Syndication »

Genetic signal prevents immune cells from turning against the body

Posted by sandiegobiotech August 13th, 2014 .
No Comments

LA JOLLA–When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers. The peacekeeping cells tell the soldier cells to halt fighting when invaders are cleared. Without this cease-fire signal, the soldiers, known as killer T cells, continue their frenzied attack and turn on the body, causing inflammation and autoimmune disorders such as allergies, asthma, rheumatoid arthritis, multiple sclerosis and type 1 diabetes.

More...

News, Syndication »

Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

Posted by sandiegobiotech August 13th, 2014 .
No Comments

Auris Medical, the Swiss biotech focused on diseases and disorders of the ear, got the catchy ticker symbol (NASDAQ: EARS) when it went public last week. But San Diego biotech ear specialist  Otonomy…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

Posted by sandiegobiotech August 13th, 2014 .
No Comments

Auris Medical, the Swiss biotech focused on diseases and disorders of the ear, got the catchy ticker symbol (NASDAQ: EARS) when it went public last week. But San Diego’s Otonomy (NASDAQ: OTIC)…

[[Click headline to continue reading.]]

More...

News, Syndication »

Shares Rise After Otonomy’s $100M IPO

Posted by sandiegobiotech August 13th, 2014 .
No Comments

Shares of Otonomy Inc. were rising Aug. 13 after the biotech drug developer’s initial public offering raised $100 million.

More...